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Abstract
One purpose of the EC funded project, SPIDIA, is to develop evidence-based quality guidelines for the pre-analytical
handling of blood samples for RNA molecular testing. To this end, two pan-European External Quality Assessments (EQAs)
were implemented. Here we report the results of the second SPIDIA-RNA EQA. This second study included modifications in
the protocol related to the blood collection process, the shipping conditions and pre-analytical specimen handling for
participants. Participating laboratories received two identical proficiency blood specimens collected in tubes with or
without an RNA stabilizer. For pre-defined specimen storage times and temperatures, laboratories were asked to perform
RNA extraction from whole blood according to their usual procedure and to return extracted RNA to the SPIDIA facility for
further analysis. These RNA samples were evaluated for purity, yield, integrity, stability, presence of interfering substances,
and gene expression levels for the validated markers of RNA stability: FOS, IL1B, IL8, GAPDH, FOSB and TNFRSF10c. Analysis
of the gene expression results of FOS, IL8, FOSB, and TNFRSF10c, however, indicated that the levels of these transcripts were
significantly affected by blood collection tube type and storage temperature. These results demonstrated that only blood
collection tubes containing a cellular RNA stabilizer allowed reliable gene expression analysis within 48 h from blood
collection for all the genes investigated. The results of these two EQAs have been proposed for use in the development of a
Technical Specification by the European Committee for Standardization.
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Introduction
SPIDIA (Standardization and Improvement of Generic Pre-
analytical Tools and Procedures for In Vitro Diagnostics; www.
spidia.eu) is a European Commission funded, four-year, integrated
project aimed at the standardization and improvement of pre-
analytical procedures for in vitro diagnostics. Project objectives are
accomplished by using evidence-based, quality assurance schemes
derived from external quality assessments (EQAs) and validated
technologies for the collection, transport and processing of blood
samples for in vitro diagnostic testing of genomic DNA, cell-free
(plasma) DNA, and intracellular RNA [1,2].
As we noted in our previous publication of results of the first
SPIDIA EQA of intracellular RNA [1], the inherent instability of
RNA makes planning a well-controlled, external evaluation of this
analyte in blood a considerable challenge. While results of the first
EQA demonstrated an association between gene expression levels
and RNA integrity number (RIN), the results did not indicate
significant differences in the expression levels of the investigated
genes as a function of storage time, temperature, or whether or not
the blood collection tube contained an RNA stabilizer. The first
EQA was conducted using pooled blood specimens from different
donors collected in citrate phosphate dextrose adenine (CPDA)
anti-coagulant. Pooled blood was aliquoted into proficiency
specimens and shipped to participating laboratories under
uncontrolled shipping conditions. These factors may have caused
ex vivo changes in expression of investigated genes before RNA
analysis. Taking into account some of the problems encountered
with this first study, we first investigated the effect on gene
expression of blood pooling, and we designed a second, expanded
EQA with some modifications related to (i) the blood collection
process, (ii) the shipping conditions and (iii) the pre-analytical
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specimen handling protocol for participating laboratories. Here we
report the results of the second SPIDIA-RNA EQA.
Since most blood specimens are collected in EDTA tubes, blood
collection for the second study was performed using bags prefilled
with an EDTA solution such that the final molar concentration
approximated that of EDTA tubes. This step was taken to obtain a
large volume of whole blood which closely resembled in
composition whole blood specimens received in clinical laborato-
ries, i.e. EDTA whole blood. Because blood from a single donor
was not of sufficient volume to provide proficiency specimens to all
study participants, two blood donors were enrolled, blood from
each donor was aliquoted into T0 control and proficiency
specimens, the resultant specimens were identified as to donor
source, and the results segregated accordingly. The participating
laboratories were therefore randomized into two groups, each
group receiving proficiency specimens associated with one donor.
To maintain constant temperature during sample shipment, we
adopted dedicated shipping containers that maintained an internal
temperature of 2uC to 8uC for 48 h.
The protocol for participants for the second EQA was virtually
the same as for the first EQA study. Briefly, two proficiency
specimens, both either with or without an RNA stabilizing
additive, were sent to participating laboratories according to
whether or not they wished to receive tubes containing stabilizer.
Participants were asked to extract the RNA from whole blood
sample from one tube immediately after receipt by the laboratory
and from the second tube 24 h later after storage at either ambient
or refrigerated temperature. Storage temperature was assigned
randomly. The participants were instructed to extract the RNA
using their routine laboratory procedure and send the purified
RNA samples back to the SPIDIA facility (Prof. M. Pazzagli,
Clinical Biochemistry Laboratory, University of Florence, ITALY)
for analysis.
The quality and quantity of RNA in the returned samples were
evaluated by means of the same methodology used in the first
SPIDIA-RNA EQA. These methods included the spectrophoto-
metric measurement of total RNA yield and purity, RIN score as
measured by the Agilent Bioanalyzer [3], expression levels of the
genes FOS, IL1B, IL8, and GAPDH [4], and detection of qPCR
inhibition [5]. In addition, the expression levels of two new
biomarkers, FOSB and TNFRSF10c, developed and validated
within the SPIDIA project, as indicators of ex vivo gene expression
changes in stored EDTA blood, were also included in order to
improve the evaluation of highly labile RNA targets [5,6–8].
The results of these two SPIDIA RNA EQA studies have been
compiled and will be used by the European Committee for
Standardization (CEN) to propose an evidence-based Technical
Specification for pre-analytical handling of blood for RNA-based
in vitro diagnostics.
Materials and Methods
Effect of blood specimen pooling on gene expression
Blood collection. Blood from 18 healthy, consented subjects
was collected into five Vacutainer K2EDTA Tubes (BD, Franklin
Lakes, NJ), after ethical approval of the A¨rztekammer Nordrhein
(German). The healthy subjects signed an informed consent. We
made six specimen pools, each pool containing one tube from each
of three randomly selected subjects. From each pool as well as
from one of the remaining EDTA tubes from each donor, a
2.5 mL aliquot was transferred into PAXgene Blood RNA Tubes
(PAXgene) (PreAnalytiX, Hombrechtikon), incubated for 6 h at
room temperature, and then frozen at 220uC. The remaining
three tubes from the individual subjects, as well as the six sample
pools were incubated at room temperature for up to 3 days. After
one, 2, and 3 days, a 2.5 mL aliquot of blood from each sample
was transferred into PAXgene tubes to stabilize the transcript
profile, incubated for 6 h at room temperature, and then frozen at
220uC. At the end of the time course, RNA from all specimens
stored in PAXgene tubes was extracted according to the PAXgene
Blood RNA Kit Handbook Version 2 and analyzed for individual
transcript levels.
PCR Analysis. Reverse Transcription quantitative PCR (RT-
qPCR) was performed using 3 mL of the RNA eluate. The one-
step qRT-PCR reactions were performed as duplex qPCR (FOS/
18SrRNA and IL1B/18SrRNA) for 40 cycles on a TaqMan 7700
cycler (ABI) using the QuantiTect Probe RT-PCR Kit (QIAGEN,
Germany) and specific primers. Relative transcript levels of FOS
and IL1B gene transcripts were determined by duplex RT-qPCR,
using 18S rRNA as an internal standard and DDCq calculation.
Statistical Analysis. A generalized linear modelling [9]
approach was implemented on the qPCR data by considering a
model including both factors together with their first order
interaction term. This model was implemented by considering the
log2(RQ) values as dependent variables where RQ=2
2DDCq and
2DDCq= [(Cqgene2Cq18S)TimeX2(Cqgene2Cq18S)Time0. Statisti-
cal analysis was performed using SAS software v. 9.2 (SAS
Institute Inc. Cary, NC).
Second SPIDIA-RNA EQA
Enrollment of Applicants. The announcement of the
second SPIDIA-RNA EQA was published on the EFLM web site
(www.efcclm.org) which listed the protocols, the application form,
and a participant questionnaire. Laboratories applying for
participation were asked to describe the type of blood collection
tube they usually use for RNA-based analyses: tubes without an
RNA stabilizer (e.g. EDTA Tube, EDTA) or with an RNA
stabilizer (e.g. the PAXgene Blood RNA Tube, PAXgene).
Details on the content of these web pages are reported as
Supporting Information. These include the protocols describing
the procedures for blood storage and RNA extraction (Protocol
S1, Protocol S2 and, Protocol S3), and the Results Form on which
to record the data (Protocol S4, Protocol S5). Three different
protocols and Results Forms were finalized depending on the type
of blood collection tube used as specified by the applicant. All
participants were informed in advance of the shipping date of the
samples.
Proficiency specimen preparation and shipment. Blood
was collected from two consented, adult donors (Donor1, ‘‘D1’’
and Donor2, ‘‘D2’’) after approval by Institutional Committee of
Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). The
donors signed a written informed consent. In order to make
enough proficiency specimens for all participating laboratories,
venous whole blood (approximately 450 mL) was collected from
each donor into a blood collection bag (MacoPharma) prefilled
with K3EDTA (1.79 mg/mL) kindly supplied by BD, Plymouth,
UK. Blood from each donor was transferred into a separate,
sterilized flask, mixed under gently stirring conditions while cooled
on ice, and immediately aliquoted into BD Vacutainer Evacuated
Secondary Tubes (ESTs) (BD) (3 mL/tube) and PAXgene tubes
(2.5 mL/tube). RNA was isolated immediately from replicate
proficiency specimens from each donor and designated as time
zero control (T0) for gene expression stability studies (Fig. 1). RNA
from T0 PAXgene Blood RNA tube specimen was extracted by
PAXgene Blood RNA Kit, 2.5mL blood from T0 EDTA tube was
transferred immediately after blood collection in PAXgene Blood
RNA tube and extracted by PAXgene Blood RNA Kit.
Depending upon the request specified in the application form,
A European EQA for Evaluation of RNA Quality
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each participating laboratory received two proficiency specimens,
‘‘Tube C’’ and ‘‘Tube D,’’ either in ESTs (EDTA whole blood) or
in PAXgene tubes. The participating laboratories were randomly
allocated into two groups: one group received two specimens from
Donor1 and the other group received two specimens from
Donor2. PAXgene tubes were incubated at room temperature
for 2 h prior to packaging according to manufacturer’s instruc-
tions. Aliquoted proficiency specimens were stored at 4uC prior to
packaging and shipment, and boxes containing cooled gel packs to
maintain 2–8 uC for 48 h were shipped by an international courier
on the same day of blood collection.
Instructions for the Participants. The laboratories were
asked to store the blood at either room temperature (RT) or 4uC
and extract the RNA at specified times after receipt. Participants
were asked to extract RNA from Tube C (RNA C) immediately
upon arrival of the tubes and from Tube D (RNA D) 24 h after
Tube C. PAXgene Tube D was stored at RT while EDTA Tube
D was stored either at RT or at 4uC according to a randomized
scheme. Tube D was therefore used only to investigate the effect of
the storage time and temperature on the quality of extracted RNA
and not for the proficiency evaluation. The two extracted RNA
samples from Tubes C and D (RNA C and RNA D) were analyzed
spectrophotometrically by the participating laboratory for con-
centration and purity (A260/A280), and both purified RNAs were
shipped on dry ice to the SPIDIA facility for further analysis.
Data reporting from participants. The participants used
the on-line Results Form (Protocol S4 and Protocol S5) to report
detailed information of the procedure used during the RNA
extraction phase. This information included the date of sample
arrival, the temperature and duration of blood sample storage,
RNA extraction protocol used, the spectrophotometric evaluation,
and temperature and duration of storage of the extracted RNA
prior to shipping.
Extracted RNA shipment and storage conditions. After
RNA extraction, the participants shipped the two RNA samples,
RNA C and RNA D, on dry ice back to the SPIDIA facility where
the extracted RNA samples were stored at 280uC until analysis.
RNA quality parameters. The RNA quality parameters
tested at the SPIDIA facility included UV spectrophotometric
analysis of RNA purity and yield as determined by the participants
and the RIN score as determined by an Agilent Bioanalyzer 2100
(Agilent Technologies) for an overall evaluation of RNA integrity.
Further testing of RNA integrity and quality included an RT-
qPCR measurement of the expression of FOS, IL1B, IL8 and
GAPDH transcripts and analysis of the RT-qPCR kinetics for the
detection of the presence of RT-qPCR inhibition. Details on the
reagents and methods used for these analyses are reported
elsewhere [1,5,10].
In particular, primers and probes for GAPDH (Pre-Developed
TaqMan Assay Reagents, P.N. 4326317E), IL1B, IL8 and FOS
(TaqMan Gene Expression Assay; Hs00174097_m1,
Hs99999034_m1, and Hs00170630_m1, respectively) were from
Life Technologies. Total RNA (400 ng) was reverse transcribed
using a TaqMan Reverse Transcription Reagents kit (Life
Technologies). Reverse transcription was performed in a final
volume of 80 mL containing 500 mM KCl, 0.1 mM EDTA,
100 mM Tris?HCl (pH 8.3), 5.5 mM MgCl2, 500 mM of each
dNTP, 2.5 mM random hexamers, 0.4 U/mL RNase inhibitor,
and 1.25 U/mL Multiscribe Reverse Transcriptase. The reverse
transcription reaction was performed at 25uC for 10 min, 48uC for
30 min, and 95uC for 3 min. Gene expression was measured by
qPCR. For each sample 12.5 ng of cDNA was added to 10 mL of
PCR mix containing a primer set and 16Universal PCR Master
Mix (Life Technologies). The samples were then subjected to 40
cycles of amplification at 95uC for 15 s and 60uC for 60 s in the
ABI PRISM 7900 Sequence Detector (Life Technologies). The
amount of each target gene was evaluated against a standard
curve. Each standard was obtained by cloning a cDNA fragment
of the specific gene (FOS, GAPDH, IL1B, and IL8) into the
plasmid pCR2.1-TOPO (Life Technologies). Each standard curve
was generated by plotting the mean Cq of the technical replicates
versus the logarithm of the known starting concentration [16].
Samples and standards were measured in qPCR triplicates. The
gene expression results are reported as log10 (copies/mg total
RNA).
In addition, two previously validated biomarkers identified
within the SPIDIA project which indicated ex vivo gene expression
changes in stored blood were used to determine the extent of gene
transcription instability in stabilized and unstabilized blood
specimens (manuscript submitted for publication). These tran-
scripts, one of which is up-regulated (FOSB) and the other down-
regulated (TNFRSF10c) in EDTA blood tubes, were quantified in
both RNA C and RNA D samples by qPCR relative quantification
against T0 controls using PPIB and GUSB genes as reference
genes. For the qPCR analysis of these four biomarkers, 2 mL of
cDNA were added in a total volume 20 mL containing a
Quantitect probe PCR master mix (Qiagen) 1x, 100 nM TaqMan
probe, 400 nM forward and reverse primers, and water and
incubated for 95uC for 15 min and 50 cycles of 95uC for 15 s and
61uC for 90 s each.
Statistical analysis and results interpretation
Evaluation of laboratory proficiency. The evaluation of
the laboratory proficiency was carried out by applying the same
approach previously described [1]. The aims of the applied
statistical procedure were to detect outlier results and/or identify
laboratories with issues related to pre-analytical handling of
specimens by calculating robust control limits (one or two sided)
and comparing lab results to these limits. These consisted of an
Action Limit (AL) and a Warning Limit (WL) [11,12]. According
to these limits, the proficiency of each participant was classified as
follows:
N Out of control: the value exceed the upper or lower AL or the
value was below the one-sided AL.
N Warning: the value was between the upper AL and WL or
between the lower AL and WL, or between the one-sided WL
and AL.
N In control: the value was between the lower and the upper WL
or exceed the one-sided WL.
The analysis and interpretation of the RT-qPCR kinetics were
performed as previously described [1,5].
Evaluation of the FOSB and TNFRSF10c
Biomarkers. The expression level of these biomarkers was
evaluated as relative to housekeeping gene transcripts by compar-
ative Cq method [13] as follows: RQ=22DDCq where: 2DDCq=
[(Cqbiomarker – Cqmeanref) Time x–(Cqbiomarker–Cqmeanref)Time 0 where
‘‘meanref’’ is the mean of the Cq values of the two housekeeping
genes, and ‘‘T0’’ designates RNA extracted immediately after blood
collection at the SPIDIA facility. The evaluation of gene expression
was performed within each donor using the corresponding T0
values.
Influence of blood collection tube type and/or storage
temperature on gene expression. The relationship between
blood collection tube type alone or in combination with storage
temperature and the gene expression levels of the four selected
genes was investigated by using a non-parametric approach
A European EQA for Evaluation of RNA Quality
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Figure 1. Schematic presentation of the workflow of the second SPIDIA-RNA EQA. Blood was drawn from two donors (D1, D2) into
separate EDTA containing bags. EST = Evacuated Secondary Tube, that does not contain any chemical formulation. T0 = Blood processed without
storage, immediately after blood collection. day 1, day 2= Time period between blood collection and RNA preparation.
doi:10.1371/journal.pone.0112293.g001
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(Kruskal-Wallis Test). The comparisons were performed by
considering the T0-adjusted scale of each variable (across-subjects
analysis). To account for multiple comparisons, a Bonferroni
correction p-value was computed.
All statistical analysis was performed using SAS software v. 9.2
(SAS Institute).
Results
Effect of blood pooling on gene expression of FOS and
IL1B
Expression levels of FOS significantly changed over time (p-
value: ,0.01) but were not significantly affected by the blood
pooling (p-value: 0.09) (Fig. 2A). IL1B showed a statistically
significant difference in expression between pooled and not-pooled
blood (p-value: ,0.01) whereas storage time was not a statistically
significant factor (p-value: 0.93) (Fig. 2B).
Second SPIDIA-RNA EQA
Applicant recruitment and questionnaire
information. One hundred twenty-two applications (approxi-
mately 50% were accredited laboratories) were received from 21
different European countries, and 119 laboratories confirmed their
participation in the second SPIDIA-RNA EQA (Fig. S1A). A
description of the structure of the participating laboratories is
reported in Figure S1B. The most frequently used analytical
applications requiring purified RNA are shown in Figure S1C.
At deadline, 109 laboratories (92%) returned extracted RNA to
the SPIDIA facility. Eighty (80) of the 109 laboratories had
received blood specimens in EST tubes (41 from Donor1 and 39
from Donor2) and the remaining 29 laboratories in PAXgene
tubes (15 from Donor1 and 14 from Donor2).
Analysis of the Questionnaire (n = 92 labs) revealed that 66% of
the laboratories typically collect blood in EDTA tubes, 21% in
PAXgene tubes, and the remaining 13% in other blood collection
tubes. The blood volume normally collected by the participating
laboratories, ranged from 1 to .10 mL, and most laboratories
perform RNA extraction within 12 h post-phlebotomy. Partici-
pants indicated that the extracted RNA is mainly used for reverse
transcription and subsequent qPCR. These data as well as
additional information describing the current methods for RNA
extraction and evaluation of RNA concentration are summarized
in Table S1. Analysis of the Result Forms revealed that only 42/
109 (39%) of the participants used the DNase treatment during
RNA extraction, even if it is well known that DNA contamination
during RNA purification can lead to non-specific amplification
and aberrant results in reverse transcription quantitative PCR
[14].
Report for the participants. At the SPIDIA facility, the
RNA samples sent from the SPIDIA participants were analyzed as
described in Materials and Methods and the results evaluated
using the statistical approach described above to produce an
individual report for each participating laboratory. In each report,
the distribution of all the data for each quality parameter was
graphically displayed in a box-plot, which included the AL and the
WL together with a red dot indicating the individual value of the
particular laboratory. A box under each graph indicated the
classification of the laboratory’s proficiency for each specific
parameter. Appendix S1 shows an example of a report for
Donor1.
Spectrophotometric data. Tables A.1 and A.2 in Appendix
S1 summarize the spectrophotometric measurement results
provided by the participants and by the SPIDIA facility along
with some details concerning times, methods, and reagents.
Sections A.3 and A.4 (Appendix A) depict box-plots of the
distributions of RNA purity and yield for RNA C reported by the
participants and measured by the SPIDIA facility.
As reported in section A.3, a similar purity distribution within
each donor was observed by using values reported by participating
laboratories (D1 median= 1.98, IQR=0.23; D2 median = 2.02,
IQR=0.21) and the SPIDIA values (D1 median= 1.98,
IQR=0.24; D2 median = 1.95, IQR=0.17) The same findings
were observed for total RNA yield (ng/mL blood, section A.4) with
a similar, within-donor distribution for both the lab values (D1
median = 2.34 ng/mL, IQR=2.21; D2 median= 2.22 ng/mL,
Figure 2. Relative Transcript levels of FOS and IL1B in individual and pools samples. Overall distribution of FOS (A) and IL1B (B) according
to time storage. Each dot represents the expression levels of each individual (black) or pool (gray) samples for each time; the dashed lines indicate the
time-trend for each sample. The continuous lines indicate the overall trend for individual (black) and pool (gray) samples. The horizontal dot-dashed
line indicates the expected value of T0.
doi:10.1371/journal.pone.0112293.g002
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IQR=2.15) and the SPIDIA values (D1 median= 1.94 ng/mL,
IQR=2.00; D2 median= 2.01 ng/mL, IQR=1.85).
RIN Scores. Section B.1 (Appendix S1) reports the distribu-
tions of RIN scores obtained from RNA C, and section B.2
(Appendix S1) shows the corresponding electropherogram. The
median value was similar in the two Donors (D1 median = 8.60,
IQR=2.10; D2 median= 8.15, IQR=2.10). The WL indicated
that the proficiency of a laboratory could be classified as ‘‘in
control’’ when the RIN score was greater than 6.90 for Donor1
and 6.62 for Donor2.
Gene expression profile. The distributions of the gene
expression [log10 (copies/mg total RNA)] of the four genes tested
are graphically represented in section C.1 (Appendix S1). For both
Donors, IL1B showed the narrowest resultant distribution and the
lowest variability in comparison to the other genes.
qPCR Kinetics analysis. In section D.1 (Appendix S1) we
reported the distribution of the Kinetics Distance (KD) obtained
by the analysis of the qPCR kinetics data by the Kineret software
procedure described by Tichopad, et al. [5]. The two lines
depicted in the figures correspond to the theoretical limits used to
detect strong (.9.21) and weak (5.9929.21) outliers. For all
transcripts, the median value is below the defined thresholds. Of
note was that results for GAPDH were available for only 22/56
(39%) and 22/53 (42%) for Donor1 and Donor2 respectively, and
therefore this parameter was not considered in the evaluation of
the overall performance of the participating laboratories.
Summary of the lab proficiency evaluation. Table E in
Appendix S1 shows the proficiency of the laboratory for RNA
quality parameters evaluated in this study. The table depicted the
results with three colors: green indicating ‘‘in control’’, yellow
indicating ‘‘warning’’ or ‘‘weak outlier’’, and red indicating ‘‘out of
control’’ or ‘‘strong outlier.’’ Missing values were designated
‘‘missing’’ in the summary table with an explanation in the
‘‘comments’’ column. All data were visually summarized as a
‘‘radar’’ graph with proficiency level symbolized by a colored
square (same colors as in the Summary Table, Table E in
Appendix S1). The distance between the colored square and the
center of the graph indicates the level of proficiency (the further
away from the center, the worse the proficiency).
Effects of blood collection tube and storage conditions on
FOSB and TNFRSF10c Biomarkers. In section F (Appendix
S1) we reported the distributions of the relative quantification of
the up- and down-regulated FOSB and TNFRS10c biomarkers
with respect to the blood collection tube (Tube C and Tube D) and
relative to both blood collection tube and storage temperature
(Tube D). In the figures, the horizontal line indicates a
log2(RQ)= 0 corresponding to the T0 value that is expected in
the absence of up- or down-regulation.
For both donors, the variations from T0 values of FOSB and
TNFRSF10c transcripts from blood collected in PAXgene tubes
were close to zero even 48 h post-phlebotomy. Messenger RNA
species from EDTA tubes, however, showed time- and temper-
ature-dependent expression levels. In particular, at 24 h post-
phlebotomy (Appendix S1, section F1 and F2, Tube C), we
observed an induction of FOSB expression in comparison to the
T0 value. Transcript copy number further increased 48 h after
collection, especially if the blood samples were stored at RT
(Kruskal-Wallis p-value ,0.01) (Appendix S1, Section F1, Tube
D). The same findings in the opposite direction were observed for
the down-regulated biomarker, TNFRSF10c (Kruskal-Wallis p-
value ,0.01) (Appendix S1, section F2, Tube D).
Overall proficiency of the participating
laboratories. On the basis of the RNA quality parameters
measured in this second SPIDIA-RNA EQA, 45% (D1) and 42%
(D2) laboratories were within non-critical proficiency limits (all
parameters classified as ‘‘in control’’ or ‘‘warning’’) whereas 29%
(D1) and 30% (D2) laboratories presented one ‘‘out of control’’
rating and/or one or more ‘‘missing data’’ responses. The
remaining participating laboratories (D1:27%, D2:28%) presented
two or more ‘‘out of control,’’ with or without ‘‘missing data’’
quality parameters (Table 1).
An overall increase in the quality of lab proficiency from the first
to the second SPIDIA-RNA EQA was observed with the
percentage of laboratories with ‘‘good’’ proficiency ratings
increasing from 26% in the first EQA to 43% (by considering
both donors) in the second EQA.
Pre-analytical factors and Gene Expression
Figure 3A and 3C show the distributions of the gene expression
analysis of FOS and IL8 with respect blood collection tube type in
RNA C and RNA D. Tube D was used to investigate the effect of
storage time, storage temperature and tube type on the quality of
extracted RNA. According to the SPIDIA protocol, participants
were instructed to store PAXgene Tube D at RT (PAX-RT) and
EDTA tubes at 4uC or RT (EDTA-4uC and EDTA-RT,
respectively), the distributions of gene expression analysis of FOS
and IL8 with respect to these protocol conditions.
For both FOS and IL8, a statistically significant difference was
observed depending upon the blood collection tube used (Fig. 3A,
3C) for both RNA C (FOS: Kruskal Wallis p-value ,0.001; IL8:
Kruskal Wallis p-value ,0.001) and RNA D (FOS: Kruskal Wallis
p-value = 0.003; IL8: Kruskal Wallis p-value ,0.001). Moreover,
we observed a relevant discrepancy between gene expression in
RNA samples depending upon storage temperature and collection
tube type (Fig. 3B, 3D). Specifically, we observed that IL8 levels
(Fig. 3D) in RNA extracted from blood samples collected in
EDTA tubes stored at RT before RNA extraction differed
significantly from that in RNA from EDTA tubes stored at 4uC
(Bonferroni adjusted p-value ,0.001) and PAXgene tube (RT)
(Bonferroni adjusted p-value ,0.001). This difference was
observed also for FOS (Fig. 3B) between RNA samples from
EDTA tubes stored at 4uC and RNA from blood collected
PAXgene tubes stored at RT (Bonferroni adjusted p-value ,
0.001).
Discussion
One of the main purposes of the SPIDIA project was to
investigate the role of pre-analytical variables in the handling of
blood samples for molecular testing. In order to obtain evidence-
based guidelines for the pre-analytical processing of blood samples
for RNA analysis, two EQAs were planned (first and second
SPIDIA-RNA). For each EQA, a survey and a proficiency testing
program was implemented to evaluate current sample handling
parameters and technologies for blood RNA-based analysis in
laboratories in Europe. In addition to providing objective
measurements for laboratory proficiency, we designed this EQA
to approximate blood collection, specimen storage, and RNA
extraction methods currently used by participating laboratories
and compare the quality of the RNA produced by these methods.
Pursuant to these goals, we collected blood into EDTA-filled
blood collection bags for this second EQA instead of in the CPDA
blood bags used in the first EQA [1]. Even if this model does not
follow the conventional procedure for blood collection for RNA
analysis (as blood sample would be drawn directly into a tube
rather than into a bag), the proposed procedure is able to provide
a blood sample that mimics a real clinical blood sample and in a
sufficient amount for the SPIDIA-RNA EQA set-up.
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Because blood from one donor was not of sufficient volume to
provide specimens for all of the participating laboratories, we
determined the effect of blood pooling on gene expression. The
results (Fig. 2) demonstrated that differential gene expression was
observed between pooled and non-pooled blood for the IL1B
transcript. Consequently, specimen pooling was abandoned as a
proficiency specimen strategy in the second EQA. Blood from two
donors were collected and aliquoted into proficiency specimens,
and the participating laboratories were randomized into two
groups, each group receiving blood specimens from only one
donor.
Relative to the first SPIDIA-RNA EQA [1], other modifications
were introduced including controlled shipping conditions (shipping
containers with a temperature maintained at 2uC to 8uC for 48 h)
and defined time and temperature storage conditions of profi-
ciency specimens prior to RNA extraction (Fig. S2).
One hundred twenty-two applications were received from 21
different European countries, 109 laboratories returned the
extracted RNA to the SPIDIA facility by the established deadline.
During the first SPIDIA-RNA EQA, there were 124 applications,
and 93 laboratories returned RNA samples to the SPIDIA facility
[1]. The high response rate from the laboratories for both EQAs
indicated a high level of interest and participation both in terms of
the number of laboratories enrolled as well as the number of
returned RNA samples (about 92% in both EQAs).
The survey queried current laboratory policies and practices
specific to specimen handling. Respondents were asked to provide
information on blood collection and extraction protocols (Table
S1). The analysis of the survey from the second SPIDIA RNA-
EQA confirmed the results obtained during the first EQA, which
was the preference to use commercially available extraction kits
(mainly silica membrane technology). The majority of the
laboratories collected blood in K2EDTA tubes (66%), whereas
others (21%) used PAXgene tubes. The quality of the extracted
RNA samples was evaluated for yield and purity by UV analysis.
Purified RNA was most often stored at 280uC, and the
predominant downstream analytical methods were PCR technol-
ogies (qualitative and quantitative RT-PCR). Other aspects of
sample handling and analysis protocols were more variable and
included the volume of blood used and time and temperature of
specimen storage post-phlebotomy.
Using the same approach adopted in the first SPIDIA EQA, we
evaluated the quality of RNA returned to the SPIDIA facility by
participating laboratories. An individual report for each laboratory
was produced which described the proficiency of the laboratory
respect to the results of the other participants. The distribution of
the results, similar within each donor (see the report in Appendix
S1), showed a median value of RNA purity (A260/A280) close to 2.0
indicating high quality RNA [15,16] for RNA C as measured both
by the participants and the SPIDIA laboratory. The same findings
were observed for total RNA yield (ng/mL blood).
In addition, the distributions of the RIN scores were similar for
the two donors. As no external reference value was adopted for the
evaluation of laboratory proficiency, we classified as ‘‘in control’’
all RIN scores above the WL of 6.90 for Donor1 and 6.62 for
Donor2. Only RIN scores $8.0 are classified as high integrity
RNA [16]. In this study, the median RIN score was $8 for both
donors (D1 median = 8.60; D2 median = 8.15) indicating high
integrity of the extracted RNA for the majority of the returned
RNA samples. The analysis of RT-qPCR kinetics revealed that
only few samples showed the presence of RT-qPCR interferences.
Taken altogether, the analysis of these RNA quality parameters
indicated that participants were proficient in the pre-analytical
aspects of specimen handling for RNA analysis. The analysis of the
gene expression in resultant RNA, however, demonstrated that
pre-analytical factors, independent of the proficiency of the
laboratory, significantly affected the quantity of some gene
transcripts relative to T0 copy numbers. Whereas a narrow
distribution of the expression levels four gene transcripts in all
Tube C samples was observed (Appendix S1, Section C, C.1), a
significant difference was evident in the expression levels of FOS
and IL8 depending upon blood collection tube type (EDTA or
PAXgene tubes) (Fig. 3A, 3C, respectively). The more homoge-
neous PAXgene sample gene expression distribution could be,
partially, due to the use of the same extraction procedure specific
for PAXgene Blood RNA tube (PAXgene Blood RNA kit).
From these results, we concluded that the presence of a
stabilizer in the PAXgene tubes apparently maintained gene
expression levels of FOS and IL8 close to those measured in T0
samples in RNA C (stored at RT for 24 h) and D (stored 48 h
post-phlebotomy) (Fig. 3A and 3C). In contrast, the gene
expression levels of FOS and IL8 in RNA isolated from EDTA
blood collection tubes stored at either 4uC or RT showed an ex
vivo gene-dependent induction 24 h after blood collection
(Fig. 3A, 3C, Tube C). For IL8, this gene induction was more
evident when blood was stored for 48 h after phlebotomy at RT
without stabilizer (Fig. 3D). Similar results were obtained with
gene expression analysis of the up- and down-regulated EDTA
biomarkers FOSB and TNFRSF10c (Appendix S1, Section F).
An analysis of individual participant reports according to our
proficiency classification scheme revealed that the distribution of
the overall proficiency ratings was similar within the two donors
Table 1. Classification of the proficiency of the laboratories.
Donor1 Donor2
Categories n % n %
all ‘‘in control’’ or ‘‘warning’’ a 25 45 22 42
one ‘‘out of control’’ and/or one or more ‘‘missing’’b 16 29 16 30
two or more ‘‘out of control’’ with or without missingc 15 27 15 28
Total of participants laboratory 56 100 53 100
aall ‘‘in control’’ or ‘‘warning’’: labs with all parameters in control or warning, without missing;
bone ‘‘out of control’’ and/or one or more ‘‘missing’’: labs with only one out of control (D1: n = 16, D2: n = 13); labs with only one missing (D1: n = 0, D2: n = 1) or
only more than one missing (D1: n = 0, D2: n = 1); labs with one out of control and one missing (D1: n = 0, D2: n = 1); labs with one out of control and more than one
missing (D1: n = 0, D2: n = 0);
ctwo or more ‘‘out of control’’ with or without ‘‘missing’’: labs with two out of control with at least one missing (D1: n = 2, D2: n = 3) or without missing (D1: n = 5,
D2: n = 6); labs with more than two out of control with at least one missing (D1: n = 3, D2: n = 3) or without missing (D1: n = 5, D2: n = 3).
doi:10.1371/journal.pone.0112293.t001
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with almost 40% of laboratories receiving ‘‘in control’’ assessment
for all the considered quality parameters. This result was an overall
increase in proficiency level in comparison to those obtained in the
first SPIDIA-RNA EQA. This improvement was most likely due to
the changes in the second EQA study design (proficiency specimen
preparation, shipping) and pre-analytical specimen handling
protocol (stringent time/temperature conditions).
In conclusion, the SPIDIA-RNA EQAs identified the most
critical steps in the pre-analytical procedure concerning blood
collection and processing for RNA testing. Furthermore, due to
the improvements we adopted in the second EQA, we were able to
make important conclusions regarding pre-analytical conditions,
which affect ex vivo changes in the gene expression profile. These
changes include gene induction, gene down-regulation, and RNA
degradation, all of which could result in erroneous measurements
of gene transcript levels [17–19]. Our results demonstrated that
the use of PAX gene RNA Blood collection tube allows reliable
gene expression analysis within 48 h from blood collection. Other
Figure 3. Blood collection tube and/or storage temperature and Gene Expression. Overall distribution of FOS and IL8 according to blood
collection tube (3A and 3C, respectively) and to storage temperature/collection tube in RNA D (3B and 3D, respectively). The box horizontal sides
identify the 25th and 75th centile, the horizontal line inside the box the median, the two whiskers correspond to minimum and maximum, and the
dashed line indicates the T0 value zero.
doi:10.1371/journal.pone.0112293.g003
A European EQA for Evaluation of RNA Quality
PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e112293
blood collection tubes containing RNA stabilizers are commer-
cially available but have not been tested in this study.
When using blood collection tubes which do not contain any
RNA profile stabilizer (i.e. EDTA blood collection tubes, mostly
used for cellular RNA analysis), it is strongly recommended to
investigate whether a specific RNA species intended to be
analyzed in the analytical test is stable after blood draw for the
duration of the entire pre-analytical workflow.
The results of these two SPIDIA RNA EQAs studies have been
proposed for use in the development of a Technical Specification
by the European Committee for Standardization (CEN).
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Figure S1 Distribution of participant laboratories (n = 124)
through European Countries (A), Structures (B) and the main
Research area (C).
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Figure S2 Schematic comparison of the general workflow of the
two SPIDIA-RNA EQAs: the first SPIDIA-RNA EQA study
published by Pazzagli M et al. [1] (left side) and the second
SPIDIA-RNA EQA reported in this publication (right side). In the
two EQAs blood was drawn from different numbers of donors into
blood bags containing different formulations of anticoagulant. In
the second EQA blood from two donors was not pooled, blood
aliquots intended to stay unstabilized were transferred into empty
evacuated tubes (EST) instead of EDTA tubes and all tubes were
shipped the same day of sample aliquoting to the participants
under improved shipping conditions as indicated. EST=Evac-
uated Secondary Tube, that does not contain any chemical
formulation. day 1, day 2, day 3=Time period between blood
collection and RNA preparation.
(TIF)
Table S1 Questionnaire: distribution frequencies. Usual proce-
dures performed by participant laboratories (n = 92).
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Appendix S1 Report for participant. Report, related to Donor1,
produced for each participant containing the overall distribution
of the analyzed RNA quality parameters and the specific
evaluation of the performance for each parameter and overall
evaluation.
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Protocol S1 Protocol A- PAXgene Blood RNA tube. Procedures
and protocol for blood storage and RNA extraction for
participants receiving blood collected in PAXgene Blood RNA
tubes.
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Protocol S2 Protocol B- EDTA tubes (+4uC). Procedures and
protocol for blood storage and RNA extraction for participants
receiving blood collected in EDTA tubes, which had to store the
blood at +4uC.
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Protocol S3 Protocol B- EDTA tubes (RT). Procedures and
protocol for blood storage and RNA extraction for participants
receiving blood collected in EDTA tubes, which had to store the
blood at RT.
(PDF)
Protocol S4 Result form – Protocol A - PAXgene Blood RNA
tubes. Form to fill by experimental data performing RNA
extraction from blood collected in PAXgene Blood RNA tubes.
(PDF)
Protocol S5 Result form – Protocol B - EDTA. Form to fill by
experimental data performing RNA extraction form blood
collected in EDTA tubes.
(PDF)
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